THE EFFECTS OF ADJUVANT CHEMOTHERAPY ON SERUM ADMA AND ENDOTHELIN-1 LEVELS IN EARLY STAGE BREAST CANCER PATIENTS (IZMIR ONCOLOGY GROUP (IZOG) STUDY

MURAT AKYOL¹, METE KARA², AHMET ALACACIOGLU², LEYLA DEMIR³, HULYA ELLIDOKUZ⁴, YUKSEL KUCUKZEYBEK², YASAR YILDIZ², VEDAT BAYOGLU², IBRAHIM YILDIZ², TARIK SALMAN², UMUT VAROL², BETUL KUCUKZEYBEK⁵, UTKU OFLAZOGLU², HALIL TASKAYNATAN², ZEHRA GUMUS², MUSTAFA OKTAY TARHAN⁴

¹Department of Medical Oncology, Manisa State Hospital, Manisa - ²Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir-Turkey - ³Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - ⁴Institute of Oncology, Dokuz Eylul University, Izmir-Turkey - ⁵Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey

Objective: We aimed to investigate changes in body composition, serum asymmetric dimethyl arginine (ADMA) and endothe- lin-1(ET-1) levels before and after adjuvant chemotherapy in early breast cancer patients.

Methods: Seventy-two patients with early breast cancer who admitted to our outpatient clinic were included in the study. Before and after chemotherapy, the anthropometric measurements and bioelectrical impedance analysis with TANITA device, body compositions, serum ADMA and ET-1 levels were recorded.

Results: There was a statistically significant increase of serum ADMA levels ( 112.10±52.24 ng/ml vs. 206.34±128.02 ng/ml, p<0.001) after chemotherapy. On the other hand, the decrease of serum ET- 1 levels was not statistically significant (2.19±6.65 vs.1.68±3.71, p=0.57). ADMA levels was similar in both of the groups treated with anthracycline or anthracycline plus taxane regi- mens. There was no relationship between serum ADMA levels and disease stage/grade, hormone or nodal status. The changes in body composition and antropometric measurements were not statistically significant.

Conclusion: The increased serum levels of ADMA could be caused by the oxidative stress, apoptosis and endothelial dysfunc- tion secondary to chemotherapy and the decreased estrogen levels. The decrease in serum ET-1 levels might be due to the inhibition of cell proliferation and angiogenesis due to adjuvant chemotherapy.